首页> 外文期刊>Chemical research in toxicology >Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.
【24h】

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.

机译:体外代谢依赖性共价结合数据能否区分肝毒性药物和非肝毒性药物?使用人肝细胞和肝脏S-9组分的分析。

获取原文
获取原文并翻译 | 示例
           

摘要

In vitro covalent binding studies in which xenobiotics are shown to undergo metabolism-dependent covalent binding to macromolecules have been commonly used to shed light on the biochemical mechanisms of xenobiotic-induced toxicity. In this paper, 18 drugs (nine hepatotoxins and nine nonhepatotoxins) were tested for their proclivity to demonstrate metabolism-dependent covalent binding to macromolecules in human liver S-9 fraction (9000 g supernatant) or human hepatocytes, as an extension to previous work that used human liver microsomes published in this journal [ Obach et al. ( 2008 ) Chem. Res. Toxicol. 21 , 1814 -1822 ]. In the S-9 fraction, seven out of the nine drugs in each category demonstrated some level of metabolism-dependent covalent binding. Inclusion of reduced glutathione, cofactors needed by conjugating enzymes, and other parameters (total daily dose and fraction of total intrinsic clearance comprised by covalent binding) improved the ability of the system to separate hepatotoxins from nonhepatotoxins to a limited extent. Covalent binding in human hepatocytes showed that six out of the nine hepatotoxins and four out of eight nonhepatotoxins demonstrated covalent binding. Taking into account estimates of total daily body burden of covalent binding from the hepatocyte data showed an improvement over other in vitro systems for distinguishing hepatotoxins from nonhepatotoxins; however, this metabolism system still displayed some false positives. Combined with the previous study using liver microsomes, these findings identify the limitations of in vitro covalent binding data for prospective prediction of hepatotoxicity for new drug candidates and highlight the need for a better understanding of the link between drug bioactivation, covalent adduct formation, and toxicity outcomes. Directly relating covalent binding to hepatotoxicity is likely an oversimplification of the process whereby adduct formation ultimately leads to toxicity. Understanding underlying complexities (e.g., which macromolecules are important covalent binding targets, interindividual differences in susceptibility, etc.) will be essential to any understanding of the problem of metabolism-dependent hepatotoxicity and predicting toxicity from in vitro experiments.
机译:体外共价结合研究通常被用来阐明异种生物诱导的毒性的生化机制,在该研究中,异种生物被证明与大分子发生了代谢依赖性共价结合。在本文中,对18种药物(9种肝毒素和9种非肝毒素)的倾向性进行了测试,以证明其与代谢相关的共价键与人肝S-9组分(9000 g上清液)或人肝细胞中的大分子结合,作为对以前工作的扩展使用了发表在该杂志上的人肝微粒体[Obach等。 (2008)化学。 Res。毒药。 21,1814 -1822]。在S-9部分中,每种类别的9种药物中有7种表现出一定程度的代谢依赖性共价结合。包括减少的谷胱甘肽,结合酶所需的辅因子和其他参数(日总剂量和共价结合所包含的总固有清除率的一部分)在一定程度上提高了系统将肝毒素与非肝毒素分离的能力。人肝细胞中的共价结合表明,九种肝毒素中的六种和八种非肝毒素中的四种表现出共价结合。考虑到肝细胞数据对共价结合的每日总身体负担的估计,与其他区分肝毒素和非肝毒素的体外系统相比,该方法有所改善。但是,这种新陈代谢系统仍然显示出一些误报。结合先前使用肝微粒体的研究,这些发现确定了体外共价结合数据在前瞻性预测新药候选者肝毒性方面的局限性,并强调需要更好地了解药物生物活化,共价加合物形成和毒性之间的联系结果。将共价结合与肝毒性直接相关可能是该过程的过度简化,由此加合物的形成最终导致了毒性。了解潜在的复杂性(例如,哪些大分子是重要的共价结合靶标,个体之间的药敏性差异等)对于理解代谢依赖性肝毒性问题并根据体外实验预测毒性至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号